Xenetic Debt To Equity from 2010 to 2024

XBIO Stock  USD 4.11  0.10  2.49%   
Xenetic Biosciences Debt To Equity yearly trend continues to be very stable with very little volatility. Debt To Equity is likely to drop to 0.67. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.7
Current Value
0.67
Quarterly Volatility
31.01426792
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Xenetic Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Xenetic Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 180.9 K, Selling General Administrative of 3.8 M or Total Revenue of 1.6 M, as well as many indicators such as Price To Sales Ratio of 1.97, Dividend Yield of 0.0 or PTB Ratio of 0.5. Xenetic financial statements analysis is a perfect complement when working with Xenetic Biosciences Valuation or Volatility modules.
  
Check out the analysis of Xenetic Biosciences Correlation against competitors.
To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.

Latest Xenetic Biosciences' Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Xenetic Biosciences over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Xenetic Biosciences' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Xenetic Biosciences' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.00 %10 Years Trend
Slightly volatile
   Debt To Equity   
       Timeline  

Xenetic Debt To Equity Regression Statistics

Arithmetic Mean8.47
Geometric Mean0.44
Coefficient Of Variation366.25
Mean Deviation14.95
Median0.61
Standard Deviation31.01
Sample Variance961.88
Range121
R-Value(0.43)
Mean Square Error847.26
R-Squared0.18
Significance0.11
Slope(2.96)
Total Sum of Squares13,466

Xenetic Debt To Equity History

2024 0.67
2023 0.7
2015 0.61
2014 0.0377
2013 0.054
2011 0.0431
2010 120.57

About Xenetic Biosciences Financial Statements

Xenetic Biosciences investors utilize fundamental indicators, such as Debt To Equity, to predict how Xenetic Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Debt To Equity 0.70  0.67 

Pair Trading with Xenetic Biosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Xenetic Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xenetic Biosciences will appreciate offsetting losses from the drop in the long position's value.

Moving against Xenetic Stock

  0.43ROIV Roivant SciencesPairCorr
The ability to find closely correlated positions to Xenetic Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xenetic Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xenetic Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xenetic Biosciences to buy it.
The correlation of Xenetic Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Xenetic Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Xenetic Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Xenetic Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Xenetic Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Xenetic Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xenetic Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xenetic Biosciences Stock:
Check out the analysis of Xenetic Biosciences Correlation against competitors.
To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenetic Biosciences. If investors know Xenetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenetic Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.66)
Revenue Per Share
1.638
Quarterly Revenue Growth
0.116
Return On Assets
(0.29)
Return On Equity
(0.49)
The market value of Xenetic Biosciences is measured differently than its book value, which is the value of Xenetic that is recorded on the company's balance sheet. Investors also form their own opinion of Xenetic Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Xenetic Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenetic Biosciences' market value can be influenced by many factors that don't directly affect Xenetic Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenetic Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenetic Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenetic Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.